Takara Bio Inc.
Stock Price Chart
2026/03/03 UpdatedPrice Trend
2026/03/03 UpdatedPrice & Trading Details
2026/03/03 UpdatedPRICE
TRADING
Analyst Recommendations 3 analysts
Updated 2026/03/01Shareholder Composition
Updated 2026/03/01Major Holders
Updated 2026/03/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
662.3K | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
416.4K | 0.00% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
282.5K | 0.00% | |
|
iShares Trust-iShares MSCI EAFE Small-Cap ETF
|
197.7K | 0.00% | |
|
DFA INVESTMENT TRUST CO-The Japanese Small Company Series
|
168.1K | +2.07% | |
|
DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT.
|
167.9K | +35.19% |
Dividend History
Updated 2026/03/01| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥17 | 0.0% |
| 2024 | ¥17 | -59.5% |
| 2023 | ¥42 | +27.3% |
| 2022 | ¥33 | +266.7% |
| 2021 | ¥9 | - |
Financial Performance
2026/03/01 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥67,699M | ¥78,142M | ¥43,505M | ¥45,039M |
| Gross Profit | ¥49,211M | ¥44,765M | ¥26,908M | ¥26,067M |
| Operating Income | ¥28,904M | ¥20,546M | ¥3,004M | ¥2,266M |
| Pretax Income | ¥27,555M | ¥21,248M | ¥2,876M | ¥2,017M |
| Net Income | ¥19,849M | ¥16,012M | ¥1,480M | ¥1,041M |
| EPS | ¥164.84 | ¥132.97 | ¥12.30 | ¥8.65 |
| Operating Margin | 42.69% | 26.29% | 6.90% | 5.03% |
| Balance Sheet | ||||
| Total Assets | ¥115,712M | ¥129,202M | ¥121,252M | ¥125,334M |
| Total Equity | ¥95,871M | ¥112,217M | ¥111,503M | ¥115,498M |
| Total Liabilities | ¥19,841M | ¥16,985M | ¥9,749M | ¥9,836M |
| Cash | ¥23,633M | ¥51,847M | ¥35,416M | ¥29,549M |
| Interest-bearing Debt | ¥1,047M | ¥972M | ¥968M | ¥1,101M |
| Equity Ratio | 82.85% | 86.85% | 91.96% | 92.15% |
| D/E Ratio | 0.01 | 0.01 | 0.01 | 0.01 |
| Cash Flow | ||||
| Operating CF | ¥6,985M | ¥36,897M | ¥1,711M | ¥5,844M |
| Investing CF | -¥7,071M | -¥6,693M | -¥13,043M | -¥10,912M |
| Financing CF | -¥2,070M | -¥4,119M | -¥5,233M | -¥2,256M |
| Free CF | -¥5,554M | ¥31,015M | -¥11,161M | -¥4,434M |
| Efficiency | ||||
| ROE | 20.70% | 14.27% | 1.33% | 0.90% |
| ROA | 17.15% | 12.39% | 1.22% | 0.83% |
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥1,360
Rating Score: - (Based on 3 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Takara Bio Inc., together with its subsidiaries, engages in the businesses of reagents, equipment, contract services, and genetic medicine in Japan, China, the rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including reagents needed for genetic and cellular research, PCR instruments, cellular analysis devices, and in vitro diagnostics for COVID-19 testing. It also provides contract services related to regenerative medicine products and contract services related to gene analysis and testing. In addition, the company is involved in commercialization of its proprietary platform technology for biologics development; development, manufacture, and sale of manufacture ancillary materials, such as RetroNectin that is used in the manufacture of gene therapy product; application for marketing authorization of NY-ESO-1 siTCR gene therapy product; and development of JAK/STAT technology suitable for CAR gene therapy and applied development of CereAAV, a brain-tropic adeno-associated virus vector. It provides its products and services through sales agents or directly to its customers. The company was incorporated in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.
